Allergic Rhino-Conjunctivitis Market Poised for Significant Growth in the Coming 10 Years Amid Increasing Therapeutic Advancements | DelveInsight [Yahoo! Finance]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Yahoo! Finance
Advances in treatment, including allergen immunotherapy and targeted biologics, are expanding therapeutic choices and improving patient outcomes. Additionally, the ongoing research and development of novel therapies, such as Immunotek's MM09, MG01 + T517, and MG56, are expected to sustain long-term market expansion. LAS VEGAS Oct. 13, 2025 /PRNewswire/ -- DelveInsight's Allergic Rhino-Conjunctivitis Market Insights report includes a comprehensive understanding of current treatment practices, allergic rhino-conjunctivitis emerging drugs, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into leading markets (the US, EU4, UK, and Japan). DelveInsight Logo Allergic Rhino-Conjunctivitis Market Summary The market size for allergic rhino-conjunctivitis in the leading markets is expected to grow significantly by 2034. The United States accounted for the highest allergic rhino-conjunctivitis treatment market size in 7MM in 2024
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix (NASDAQ:OCUL) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.MarketBeat
- Ocular Therapeutix™ Announces First Patient Randomized in HELIOS-3 Phase 3 Registrational Program for AXPAXLI™ in NPDRGlobeNewswire
- Ocular Therapeutix (NASDAQ:OCUL) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OCUL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreetMarketBeat
- Ocular Therapeutix (OCUL) Soars 5% Ahead of Health Conferences [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix (NASDAQ:OCUL) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=OCUL&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreMarketBeat
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- 11/26/25 - Form 4
- OCUL's page on the SEC website